Literature DB >> 16238911

Solifenacin versus tolterodine--a head-to-head study: finally! But not final?

David R Staskin, Roger R Dmochowski, Alan J Wein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16238911     DOI： 10.1007/s11934-005-0032-3

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


× No keyword cloud information.
  5 in total

1.  Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.

Authors:  R A Appell; P Sand; R Dmochowski; R Anderson; N Zinner; D Lama; M Roach; J Miklos; D Saltzstein; T Boone; D R Staskin; D Albrecht
Journal:  Mayo Clin Proc       Date:  2001-04       Impact factor: 7.616

2.  Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group.

Authors:  R U Anderson; D Mobley; B Blank; D Saltzstein; J Susset; J S Brown
Journal:  J Urol       Date:  1999-06       Impact factor: 7.450

3.  Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group.

Authors:  D M Gleason; J Susset; C White; D R Munoz; P K Sand
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

4.  Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.

Authors:  Ananias C Diokno; Rodney A Appell; Peter K Sand; Roger R Dmochowski; Bernard M Gburek; Ira W Klimberg; Sherron H Kell
Journal:  Mayo Clin Proc       Date:  2003-06       Impact factor: 7.616

Review 5.  Overactive bladder: improving the efficacy of anticholinergics by dose escalation.

Authors:  Scott A MacDiarmid
Journal:  Curr Urol Rep       Date:  2003-12       Impact factor: 2.862
  5 in total
  1 in total

1.  [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].

Authors:  C Chapple
Journal:  Urologe A       Date:  2007-04       Impact factor: 0.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.